+

WO2004020595A8 - Nouveaux polypeptides humains codes par des polynucleotides - Google Patents

Nouveaux polypeptides humains codes par des polynucleotides

Info

Publication number
WO2004020595A8
WO2004020595A8 PCT/US2003/027107 US0327107W WO2004020595A8 WO 2004020595 A8 WO2004020595 A8 WO 2004020595A8 US 0327107 W US0327107 W US 0327107W WO 2004020595 A8 WO2004020595 A8 WO 2004020595A8
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides encoded
novel human
human polypeptides
modulators
Prior art date
Application number
PCT/US2003/027107
Other languages
English (en)
Other versions
WO2004020595A3 (fr
WO2004020595A2 (fr
Inventor
Lewis T Williams
Keting Chu
Ernestine Lee
Kevin Hestir
Original Assignee
Five Prime Therapeutics Inc
Riken The Inst Of Physical And
Dnaform Kk
Lewis T Williams
Keting Chu
Ernestine Lee
Kevin Hestir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Riken The Inst Of Physical And, Dnaform Kk, Lewis T Williams, Keting Chu, Ernestine Lee, Kevin Hestir filed Critical Five Prime Therapeutics Inc
Priority to AU2003274935A priority Critical patent/AU2003274935A1/en
Publication of WO2004020595A2 publication Critical patent/WO2004020595A2/fr
Publication of WO2004020595A8 publication Critical patent/WO2004020595A8/fr
Publication of WO2004020595A3 publication Critical patent/WO2004020595A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouveaux polynucléotides, à des polypeptides associés, à des compositions d'acides nucléiques et de polypeptides associées, et à des modulateurs associés tels que des anticorps et des modulateurs de petites molécules. Ces compositions sont utiles pour traiter les affections prolifératives, telles que les cancers, les affections inflammatoires immunes, bactériennes et virales.
PCT/US2003/027107 2002-08-29 2003-08-28 Nouveaux polypeptides humains codes par des polynucleotides WO2004020595A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274935A AU2003274935A1 (en) 2002-08-29 2003-08-28 Novel human polypeptides encoded by polynucleotides

Applications Claiming Priority (68)

Application Number Priority Date Filing Date Title
US40664002P 2002-08-29 2002-08-29
US40661202P 2002-08-29 2002-08-29
US40666602P 2002-08-29 2002-08-29
US40661602P 2002-08-29 2002-08-29
US40657602P 2002-08-29 2002-08-29
US40661102P 2002-08-29 2002-08-29
US40665502P 2002-08-29 2002-08-29
US60/406,576 2002-08-29
US60/406,611 2002-08-29
US60/406,616 2002-08-29
US60/406,612 2002-08-29
US60/406,666 2002-08-29
US60/406,655 2002-08-29
US60/406,640 2002-08-29
US41101902P 2002-09-17 2002-09-17
US41096002P 2002-09-17 2002-09-17
US41095702P 2002-09-17 2002-09-17
US41095302P 2002-09-17 2002-09-17
US41104602P 2002-09-17 2002-09-17
US41094602P 2002-09-17 2002-09-17
US41111102P 2002-09-17 2002-09-17
US41103702P 2002-09-17 2002-09-17
US41096202P 2002-09-17 2002-09-17
US41102402P 2002-09-17 2002-09-17
US41102202P 2002-09-17 2002-09-17
US41105202P 2002-09-17 2002-09-17
US41108202P 2002-09-17 2002-09-17
US41095102P 2002-09-17 2002-09-17
US60/411,037 2002-09-17
US60/411,052 2002-09-17
US60/411,046 2002-09-17
US60/410,957 2002-09-17
US60/410,960 2002-09-17
US60/411,024 2002-09-17
US60/411,082 2002-09-17
US60/410,946 2002-09-17
US60/411,019 2002-09-17
US60/410,951 2002-09-17
US60/411,111 2002-09-17
US60/410,953 2002-09-17
US60/410,962 2002-09-17
US60/411,022 2002-09-17
US46373203P 2003-04-18 2003-04-18
US46370003P 2003-04-18 2003-04-18
US60/463,732 2003-04-18
US60/463,700 2003-04-18
US46720303P 2003-05-02 2003-05-02
US46723003P 2003-05-02 2003-05-02
US60/467,203 2003-05-02
US60/467,230 2003-05-02
US47130603P 2003-05-19 2003-05-19
US60,471,306 2003-05-19
US47242003P 2003-05-22 2003-05-22
US60/472,420 2003-05-22
US47660903P 2003-06-09 2003-06-09
US60/476,609 2003-06-09
US48532503P 2003-07-08 2003-07-08
US48522303P 2003-07-08 2003-07-08
US60/485,325 2003-07-08
US60/485,223 2003-07-08
US48648003P 2003-07-14 2003-07-14
US60/486,480 2003-07-14
US48696003P 2003-07-15 2003-07-15
US60/486,960 2003-07-15
US49337003P 2003-08-08 2003-08-08
US49357303P 2003-08-08 2003-08-08
US60/493,573 2003-08-08
US60/493,370 2003-08-08

Publications (3)

Publication Number Publication Date
WO2004020595A2 WO2004020595A2 (fr) 2004-03-11
WO2004020595A8 true WO2004020595A8 (fr) 2004-07-15
WO2004020595A3 WO2004020595A3 (fr) 2006-05-04

Family

ID=32686486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027107 WO2004020595A2 (fr) 2002-08-29 2003-08-28 Nouveaux polypeptides humains codes par des polynucleotides

Country Status (1)

Country Link
WO (1) WO2004020595A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725249B1 (fr) 2003-11-06 2014-01-08 Seattle Genetics, Inc. Composes de monomethylvaline capables de conjugaison aux ligands
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
MX2008013756A (es) * 2006-05-05 2009-03-26 Universiteit Maastricht Carim Peptidos para uso en el diagnostico de la presencia de lesiones ateroscleroticas rotas en un individuo.
US9267946B2 (en) 2009-03-30 2016-02-23 Inserm (Institut National De La Sante Et De La Rec Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
EP2475391B1 (fr) 2009-09-09 2018-09-12 Centrose, LLC Conjugués médicamenteux ciblés à visée extracellulaire
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
CA2799540A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
SMT201900017T1 (it) 2012-10-12 2019-02-28 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
WO2014057122A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps anti-cd22 - pyrrolobenzodiazépine
SMT201800600T1 (it) 2012-10-12 2019-01-11 Medimmune Ltd Coniugati di anticorpi pirrolobenzodiazepina anti-psma
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105307685B (zh) 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
ES2731779T3 (es) 2013-03-13 2019-11-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépines
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CA2928952A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes peptidomimetiques et conjugues anticorps-medicament de ceux-ci
EP3082876B1 (fr) 2013-12-16 2018-01-17 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (fr) 2014-12-03 2017-10-11 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PT3544636T (pt) 2017-02-08 2021-05-04 Medimmune Ltd Conjugados de anticorpos-pirrolobenzodiazepinas
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
KR102189731B1 (ko) 2017-04-18 2020-12-11 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
MX384245B (es) 2017-08-18 2025-03-14 Medimmune Ltd Conjugados de pirrolobenzodiazepina
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AU2020242747A1 (en) 2019-03-15 2021-09-16 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CN111259667A (zh) * 2020-01-16 2020-06-09 上海国民集团健康科技有限公司 一种中医分词算法
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2004020595A3 (fr) 2006-05-04
WO2004020595A2 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004020595A3 (fr) Nouveaux polypeptides humains codes par des polynucleotides
WO2004035732A3 (fr) Polypeptides humains codes par des polynucleotides et procedes d'utilisation de ces polypeptides
WO2002024909A3 (fr) Acides nucleiques et polypeptides de nouveau recepteur
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
HK1120556A1 (en) Neurotrophic factors
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
WO2003018758A3 (fr) Reactifs et methodes utilises dans des therapies du muscle lisse
WO2004093804A3 (fr) Polypeptides humains codes par des polynucleotides et methodes d'utilisation associees
WO2007087053A3 (fr) Compositions à base de variantes de bmp-7, procédés et utilisations
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2004094651A3 (fr) Nouveaux polypeptides humains codes par des polynucleotides
MXPA03006218A (es) Receptor de citosina tipo 2 y acidos nucleicos que codifican para lo mismo.
WO2004020591A3 (fr) Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides
WO2004038003A3 (fr) Polypeptides humains codes par des polynucleotides et methodes d'utilisation
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres
WO2003055980A3 (fr) Molecules du type il-17 et utilisations associees
WO2004039952A8 (fr) Procedes d'utilisation de polypeptides humains codes par des polynucleotides
WO2005085280A3 (fr) Clones d'adnc humains comportant des polynucleotides et leurs procedes d'utilisation
WO2004078130A3 (fr) Proteines d'interaction posh et procedes connexes
WO2004039319A3 (fr) Nouveaux polypeptides humains codes par des polynucleotides
WO2004046310A3 (fr) Nouveaux polypeptides de souris codes par des polynucleotides et leurs procedes d'utilisation
WO2004089302A3 (fr) Polypeptides posh, complexes et procedes correspondants
WO2002072632A3 (fr) Acides nucleiques du gene abcc11 humain, vecteurs contenant lesdits acides nucleiques et leurs utilisations
WO2001036478A3 (fr) Methodes et compositions se rapportant a des polypeptides et a des polynucleotides similaires au facteur bactericide augmentant la permeabilite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 11/2004 UNDER (30) ADD "60/463,732 18 APRIL 2003 (18.04.2003) US; 60/463,700 18 APRIL 2003 (18.04.2003) US; 60/467,230 02 MAY 2003 (02.05.2003) US; 60/467,203 02 MAY 2003 (02.05.2003) US; 60/471,306 19 MAY 2003 (19.05.2003) US; 60/472,420 22 MAY 2003 (22.05.2003) US; 60/476,609 09 JUNE 2003 (09.06.2003) US; 60/485,223 08 JULY 2003 (08.07.2003) US; 60/485,325 08 JULY 2003 (08.07.2003) US; 60/486,480 14 JULY 203 (14.07.2003) US; 60/486,960 15 JULY 2003 (15.07.2003) US; 60/493,573 08 AUGUST 2003 (08.08.2003) US; 60/493,370 08 AUGUST 2003 (08.08.2003) US"

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载